Keywords: patients, using, b-ms, zerit, do, better, after

Patients using B-MS' Zerit do better after switching from Glaxo

Article | 29 May 1995

Print This

- New data from the ACTG 019 study of Bristol-Myers Squibb's Zerit (stavudine) has shown that patients who had been using Glaxo ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in